S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12

Trevi Therapeutics Insider Trades

-0.10 (-7.52 %)
(As of 10/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume532,187 shs
Average Volume175,140 shs
Market Capitalization$29.51 million
P/E RatioN/A
Dividend YieldN/A

Trevi Therapeutics (NASDAQ:TRVI) Insider Buying and Selling Activity

47.30% of Trevi Therapeutics' shares are owned by company executives, directors and other insiders.
Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Trevi Therapeutics (NASDAQ TRVI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2020Enterprise Associates 16 NewMajor ShareholderSell564$2.66$1,500.24  
5/9/2019Anne VanlentDirectorBuy5,000$10.00$50,000.00  
5/9/2019Invest A/S LundbeckfondMajor ShareholderBuy375,000$10.00$3,750,000.00  
5/9/2019Jennifer L GoodInsiderBuy11,250$10.00$112,500.00  
(Data available from 1/1/2013 forward)

Trevi Therapeutics (NASDAQ:TRVI) Insider Trade Frequently Asked Questions

Who is on Trevi Therapeutics's Insider Roster?

The list of insiders at Trevi Therapeutics includes Anne Vanlent, Enterprise Associates 16 New, Invest A/S Lundbeckfond, and Jennifer L Good.Learn more on TRVI's insiders

What percentage of Trevi Therapeutics stock is owned by insiders?

47.30% of Trevi Therapeutics stock is owned by insiders. Learn more on TRVI's insider holdings

Which Trevi Therapeutics insiders have been selling company stock?

The following insider sold Trevi Therapeutics stock in the last 24 months: Enterprise Associates 16 New ($1,500.24).

How much insider selling is happening at Trevi Therapeutics?

Insiders have sold a total of 564 Trevi Therapeutics shares in the last 24 months for a total of $1,500.24 sold.

This page was last updated on 10/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.